Study Reveals Deficiencies in Immune Cells of Cystic Fibrosis Patients
How ‘Pac-Man’ cells fail to prevent deadly infection risk in people with cystic fibrosis
Image: The University Of Queensland
Researchers from The University of Queensland have identified critical deficiencies in macrophages, the immune cells responsible for fighting infections, in people with cystic fibrosis (CF). These defects hinder their ability to combat mycobacterium abscessus (MABS), a major infection risk that complicates treatment and increases mortality.
- 01Macrophages in cystic fibrosis patients exhibit multiple defects, making them less effective at fighting infections.
- 02Mycobacterium abscessus (MABS) is particularly dangerous due to its antibiotic resistance and is a leading cause of death for CF patients.
- 03Deficiencies in CF macrophages include impaired recognition and killing of pathogens, reduced zinc transport, and mitochondrial dysfunction.
- 04The current CF treatment, Elexacaftor-tezacaftor-ivacaftor (ETI), does not enhance macrophage function against MABS.
- 05Further research is needed to develop strategies that improve macrophage activity to combat infections in CF patients.
Advertisement
In-Article Ad
A recent study led by Professor Peter Sly and Dr Abdullah Tarique at The University of Queensland has uncovered significant deficiencies in the immune cells known as macrophages in individuals with cystic fibrosis (CF). These 'Pac-Man' cells are crucial for detecting and eliminating pathogens, including mycobacterium abscessus (MABS), which poses a severe infection risk for CF patients. The research highlights that CF macrophages are less effective due to several defects: they struggle to recognize and destroy bacteria, have reduced zinc transport capabilities, and exhibit mitochondrial dysfunction, which limits their ability to produce reactive oxygen species necessary for killing bacteria. Despite advancements in CF treatment with Elexacaftor-tezacaftor-ivacaftor (ETI), this therapy does not improve macrophage function, leaving patients vulnerable to infections. The findings underscore the urgent need for further research to enhance macrophage activity and develop effective strategies to combat MABS, which is increasingly resistant to antibiotics and a leading cause of mortality in CF patients.
Advertisement
In-Article Ad
The findings could lead to improved treatment strategies for cystic fibrosis patients, potentially reducing the incidence of life-threatening infections.
Advertisement
In-Article Ad
Reader Poll
How important do you think it is to enhance immune function in cystic fibrosis patients?
Connecting to poll...
Read the original article
Visit the source for the complete story.